Phase 3 Parkinson's Disease Trial, Recruiting NCT06785298 Sponsor: Tanta University Condition: Parkinson's Disease
Back to Parkinsons Disease

Phase 3 Parkinson's Disease Trial, Recruiting

NCT06785298
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 50 years or older, both male and female
  • People who have been diagnosed with Parkinson's disease and are currently taking dopamine replacement therapy
  • People whose Parkinson's disease severity falls within stages 1 to 4 on the Modified Hoehn and Yahr scale (a standard scale used to measure how advanced Parkinson's disease is — confirm with trial site if unsure which stage applies)

Who may not be able to join:

  • People who have a form of parkinsonism that is not standard Parkinson's disease, or whose parkinsonism was caused by medication
  • People who are currently breastfeeding
  • People who are pregnant or planning to become pregnant
  • People who have significant problems with their liver or kidney function
  • People who have a history of, or currently have, acute (sudden or severe) heart disease
  • People who misuse alcohol or drugs
  • People who have a known allergy to any of the medications used in the study
  • People who have other medical conditions that could affect the study results or put them at risk

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 7 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 0201067831661

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Tanta University
Registry
ClinicalTrials.gov
Start date
10 December 2024
Est. completion
10 December 2026

Where this trial is recruiting

🇪🇬 Egypt

Primary endpoints

The primary outcome is the change in quality of life in Parkinson's disease by Unified Parkinson's Disease Rating Scale

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov